MNG1002
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.683
- INTERFERON_GAMMA_RESPONSE+0.555
- INFLAMMATORY_RESPONSE+0.401
- ALLOGRAFT_REJECTION+0.374
- PROTEIN_SECRETION+0.320
- TNFA_SIGNALING_VIA_NFKB+0.316
- IL6_JAK_STAT3_SIGNALING+0.299
- COMPLEMENT+0.282
- IL2_STAT5_SIGNALING+0.274
- HEME_METABOLISM+0.269
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.355
- PANCREAS_BETA_CELLS-0.355
- HEDGEHOG_SIGNALING-0.347
- SPERMATOGENESIS-0.318
- APICAL_JUNCTION-0.219
- ANGIOGENESIS-0.181
- TGF_BETA_SIGNALING-0.162
- APICAL_SURFACE-0.159
- COAGULATION-0.136
- KRAS_SIGNALING_DN-0.136
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1415337 | GTEX | — | 0.829 |
| 2 | MNG634 | — | — | 0.823 |
| 3 | SRR12696807 | — | — | 0.815 |
| 4 | SRR1369148 | GTEX | — | 0.811 |
| 5 | SRR1402882 | GTEX | — | 0.807 |
| 6 | MNG1190 | — | — | 0.799 |
| 7 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.797 |
| 8 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.793 |
| 9 | MNG1186 | — | — | 0.789 |
| 10 | ERR2208960 | — | — | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.683 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.555 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.401 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.374 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.316 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.299 | Inavolisib | — uncovered |
| COMPLEMENT | 0.282 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.274 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.269 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.256 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.254 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.243 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.241 | Idelalisib | — uncovered |
| APOPTOSIS | 0.234 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.216 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.215 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.197 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.192 | Inavolisib | — uncovered |
| HYPOXIA | 0.179 | Idelalisib | — uncovered |